How might this patient’s moderate level of disease burden impact response to targeted therapy?
There’s a clear association, as seen in a recent study that was published in theJournal of Clinical Oncology
CASE: Metastatic Melanoma
Charles, a 62-year-old Caucasian landscaper, presented to his primary care physician with fatigue, dyspnea upon exertion, and a nonproductive cough that has lasted for 6 to 8 weeks. .
Treatment was initiated with the combination of BRAF and MEK inhibitors.